RA

Rahul Ali Sarkar

Active Director Director DIN 10188040
DIN 10188040 First appointment Jul 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2023
Shareholding value •••• Premium profile

About Rahul Ali Sarkar

Data last updated:

Rahul Ali Sarkar is a Director at Alsina Pharmaceutical Private Limited (since 2023). The company operates in Pharma. Alsina Pharmaceutical Private Limited reported revenue of ₹84,472 (FY 2023).

DIN 10188040
Primary Designation Director
Industry Pharma
First Appointment 17 Jul 2023
Oldest Company Age 4 yrs
Largest company Alsina Pharmaceutical Private Limited · ₹84,472 (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director17 Jul 20232022₹84,472 (FY 2023)Active

Board colleagues of Rahul Ali Sarkar

Directorship timeline

Open interactive timeline →
Alsina Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Rahul Ali Sarkar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahul Ali Sarkar

Rahul Ali Sarkar currently holds 1 directorship: Alsina Pharmaceutical Private Limited (Director, since 17 Jul 2023, revenue ₹84,472 (FY 2023)).

Rahul Ali Sarkar was first appointed on 17 Jul 2023 as Director at Alsina Pharmaceutical Private Limited.

The current boards of Rahul Ali Sarkar's companies include Manjurul Amin (Alsina Pharmaceutical Private Limited), Safia Begam (Alsina Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available